NADOLOL

Generic: NADOLOL

Alembic Pharmaceuticals LimitedManufacturer
ORALRoute
NADOLOLActive Substance
2023-06-02Original Approval

NADOLOL is FDA application ANDA211763, sponsored by ALEMBIC. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Class II2021-03-15
Nadolol Tablets, USP 40 mg 100 Tablets Rx Only NDC 69097-868-07 Manufactured for: Cipla USA Inc. 9100 S. Dadeland Blvd.,

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Top Reported Reactions

1
DRUG INEFFECTIVE
1,305 reports
2
MACULAR DEGENERATION
831 reports
3
NAUSEA
672 reports
4
HEADACHE
603 reports
5
OFF LABEL USE
603 reports
6
FATIGUE
526 reports
7
PAIN
513 reports
8
WEIGHT DECREASED
463 reports
9
DIARRHOEA
442 reports
10
MALAISE
419 reports